<DOC>
	<DOCNO>NCT00522574</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability XL019 adult myelofibrosis . XL019 selective inhibitor cytoplasmic tyrosine kinase JAK2 . JAK2 activate cytokine growth factor receptor phosphorylates member STAT family inducible transcription factor . Activation JAK/STAT pathway promotes cell growth survival , common feature human tumor . JAK2 activate mutation majority patient myelofibrosis , polycythemia vera essential thrombocytosis appear drive inappropriate growth blood cell condition .</brief_summary>
	<brief_title>A Safety Study XL019 Adults With Myelofibrosis</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>The subject primary myelofibrosis ( PMF ) , postpolycythemia vera MF , postessential thrombocythemia MF require therapy , include subject receive prior MFdirected therapy relapse subject refractory disease ; newly diagnose , intermediate high risk accord Lille scoring system . The subject unwilling undergo candidate peripheral stem cell/bone marrow transplant . The subject ≥18 year old . The subject Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 . The subject adequate organ function . The subject capability understanding informed consent document sign informed consent document . Sexually active subject ( male female ) must use medically acceptable method contraception course study . Female subject childbearing potential must negative pregnancy test screening . The subject diagnosis malignancy evidence malignancy 2 year prior screen study ( except nonmelanoma skin cancer situ carcinoma cervix ) . The subject uncontrolled intercurrent illness include , limited , ongoing active infection , hypertension , symptomatic congestive heart failure , unstable angina pectoris , myocardial infarction within 3 month , cardiac arrhythmia . The subject pregnant breastfeeding . The subject know positive human immunodeficiency virus ( HIV ) . The subject unable unwilling abide study protocol cooperate fully investigator designee .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Myeloproliferative Disorders</keyword>
</DOC>